Recombinant activated factor VII in cardiac surgery – first, do no harm
2007
Concerns About Recombinant Activated Factor VII in Cardiac Surgery
publication
Evidence: moderate
Author Information
Author(s): Warren Oliver J, Ara W Darzi, Thanos Athanasiou
Primary Institution: Imperial College London
Hypothesis
What are the risks associated with using recombinant activated factor VII in patients undergoing cardiac surgery?
Conclusion
Patients undergoing VAD surgery may be at a higher risk of thromboembolic events when administered rFVIIa.
Supporting Evidence
- The authors argue that the pro-coagulatory effect of rFVIIa may not function the same way in patients with VAD.
- Significant controversy exists regarding the role of tissue factor in cardiac surgery patients.
- Evidence suggests that the risk of thromboembolic events may be underestimated in the literature.
Takeaway
Using a special medicine called rFVIIa in heart surgery might cause serious blood clots, so doctors need to be very careful.
Potential Biases
There is a high risk of publication and selection bias due to the nature of the data sources.
Limitations
The study relies on existing literature, which may have biases and underreporting of adverse events.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website